Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

Tatsuhiro Shibata, Tsutomu Ohta, Kit I. Tong, Akiko Kokubu, Reiko Odogawa, Koji Tsuta, Hisao Asamura, Masayuki Yamamoto, Setsuo Hirohashi

研究成果: Article

422 引用 (Scopus)

抄録

The nuclear factor E2-related factor 2 (Nrf2) is a master transcriptional activator of genes encoding numerous cytoprotective enzymes that are induced in response to environmental and endogenously derived oxidative/electrophilic agents. Under normal, nonstressed circumstances, low cellular concentrations of Nrf2 are maintained by proteasomal degradation through a Keap1-Cul3-Roc1- dependent mechanism. A model for Nrf2 activation has been proposed in which two amino-terminal motifs, DLG and ETGE, promote efficient ubiquitination and rapid turnover; known as the two-site substrate recognition/hinge and latch model. Here, we show that in human cancer, somatic mutations occur in the coding region of NRF2, especially among patients with a history of smoking or suffering from squamous cell carcinoma; in the latter case, this leads to poor prognosis. These mutations specifically alter amino acids in the DLG or ETGE motifs, resulting in aberrant cellular accumulation of Nrf2. Mutant Nrf2 cells display constitutive induction of cytoprotective enzymes and drug efflux pumps, which are insensitive to Keap1-mediated regulation. Suppression of Nrf2 protein levels by siRNA knockdown sensitized cancer cells to oxidative stress and chemotherapeutic reagents. Our results strongly support the contention that constitutive Nrf2 activation affords cancer cells with undue protection from their inherently stressed microenvironment and anti-cancer treatments. Hence, inactivation of the Nrf2 pathway may represent a therapeutic strategy to reinforce current treatments for malignancy. Congruously, the present study also provides in vivo validation of the two-site substrate recognition model for Nrf2 activation by the Keap1-Cul3-based E3 ligase.

元の言語English
ページ(範囲)13568-13573
ページ数6
ジャーナルProceedings of the National Academy of Sciences of the United States of America
105
発行部数36
DOI
出版物ステータスPublished - 2008 9 9
外部発表Yes

Fingerprint

NF-E2-Related Factor 2
Ubiquitin-Protein Ligases
Mutation
Neoplasms
Enzyme Induction
Tumor Microenvironment
Ubiquitination
Small Interfering RNA
Squamous Cell Carcinoma
Oxidative Stress
Therapeutics
Smoking

ASJC Scopus subject areas

  • Genetics
  • General

これを引用

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. / Shibata, Tatsuhiro; Ohta, Tsutomu; Tong, Kit I.; Kokubu, Akiko; Odogawa, Reiko; Tsuta, Koji; Asamura, Hisao; Yamamoto, Masayuki; Hirohashi, Setsuo.

:: Proceedings of the National Academy of Sciences of the United States of America, 巻 105, 番号 36, 09.09.2008, p. 13568-13573.

研究成果: Article

Shibata, Tatsuhiro ; Ohta, Tsutomu ; Tong, Kit I. ; Kokubu, Akiko ; Odogawa, Reiko ; Tsuta, Koji ; Asamura, Hisao ; Yamamoto, Masayuki ; Hirohashi, Setsuo. / Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. :: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; 巻 105, 番号 36. pp. 13568-13573.
@article{f5f7196123194886a59541e3b114023b,
title = "Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy",
abstract = "The nuclear factor E2-related factor 2 (Nrf2) is a master transcriptional activator of genes encoding numerous cytoprotective enzymes that are induced in response to environmental and endogenously derived oxidative/electrophilic agents. Under normal, nonstressed circumstances, low cellular concentrations of Nrf2 are maintained by proteasomal degradation through a Keap1-Cul3-Roc1- dependent mechanism. A model for Nrf2 activation has been proposed in which two amino-terminal motifs, DLG and ETGE, promote efficient ubiquitination and rapid turnover; known as the two-site substrate recognition/hinge and latch model. Here, we show that in human cancer, somatic mutations occur in the coding region of NRF2, especially among patients with a history of smoking or suffering from squamous cell carcinoma; in the latter case, this leads to poor prognosis. These mutations specifically alter amino acids in the DLG or ETGE motifs, resulting in aberrant cellular accumulation of Nrf2. Mutant Nrf2 cells display constitutive induction of cytoprotective enzymes and drug efflux pumps, which are insensitive to Keap1-mediated regulation. Suppression of Nrf2 protein levels by siRNA knockdown sensitized cancer cells to oxidative stress and chemotherapeutic reagents. Our results strongly support the contention that constitutive Nrf2 activation affords cancer cells with undue protection from their inherently stressed microenvironment and anti-cancer treatments. Hence, inactivation of the Nrf2 pathway may represent a therapeutic strategy to reinforce current treatments for malignancy. Congruously, the present study also provides in vivo validation of the two-site substrate recognition model for Nrf2 activation by the Keap1-Cul3-based E3 ligase.",
keywords = "Cancer cell microenvironment, Multidrug resistant-associated protein, Oxidative stress, Somatic mutation, Ubiquitin-proteasome system",
author = "Tatsuhiro Shibata and Tsutomu Ohta and Tong, {Kit I.} and Akiko Kokubu and Reiko Odogawa and Koji Tsuta and Hisao Asamura and Masayuki Yamamoto and Setsuo Hirohashi",
year = "2008",
month = "9",
day = "9",
doi = "10.1073/pnas.0806268105",
language = "English",
volume = "105",
pages = "13568--13573",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "36",

}

TY - JOUR

T1 - Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

AU - Shibata, Tatsuhiro

AU - Ohta, Tsutomu

AU - Tong, Kit I.

AU - Kokubu, Akiko

AU - Odogawa, Reiko

AU - Tsuta, Koji

AU - Asamura, Hisao

AU - Yamamoto, Masayuki

AU - Hirohashi, Setsuo

PY - 2008/9/9

Y1 - 2008/9/9

N2 - The nuclear factor E2-related factor 2 (Nrf2) is a master transcriptional activator of genes encoding numerous cytoprotective enzymes that are induced in response to environmental and endogenously derived oxidative/electrophilic agents. Under normal, nonstressed circumstances, low cellular concentrations of Nrf2 are maintained by proteasomal degradation through a Keap1-Cul3-Roc1- dependent mechanism. A model for Nrf2 activation has been proposed in which two amino-terminal motifs, DLG and ETGE, promote efficient ubiquitination and rapid turnover; known as the two-site substrate recognition/hinge and latch model. Here, we show that in human cancer, somatic mutations occur in the coding region of NRF2, especially among patients with a history of smoking or suffering from squamous cell carcinoma; in the latter case, this leads to poor prognosis. These mutations specifically alter amino acids in the DLG or ETGE motifs, resulting in aberrant cellular accumulation of Nrf2. Mutant Nrf2 cells display constitutive induction of cytoprotective enzymes and drug efflux pumps, which are insensitive to Keap1-mediated regulation. Suppression of Nrf2 protein levels by siRNA knockdown sensitized cancer cells to oxidative stress and chemotherapeutic reagents. Our results strongly support the contention that constitutive Nrf2 activation affords cancer cells with undue protection from their inherently stressed microenvironment and anti-cancer treatments. Hence, inactivation of the Nrf2 pathway may represent a therapeutic strategy to reinforce current treatments for malignancy. Congruously, the present study also provides in vivo validation of the two-site substrate recognition model for Nrf2 activation by the Keap1-Cul3-based E3 ligase.

AB - The nuclear factor E2-related factor 2 (Nrf2) is a master transcriptional activator of genes encoding numerous cytoprotective enzymes that are induced in response to environmental and endogenously derived oxidative/electrophilic agents. Under normal, nonstressed circumstances, low cellular concentrations of Nrf2 are maintained by proteasomal degradation through a Keap1-Cul3-Roc1- dependent mechanism. A model for Nrf2 activation has been proposed in which two amino-terminal motifs, DLG and ETGE, promote efficient ubiquitination and rapid turnover; known as the two-site substrate recognition/hinge and latch model. Here, we show that in human cancer, somatic mutations occur in the coding region of NRF2, especially among patients with a history of smoking or suffering from squamous cell carcinoma; in the latter case, this leads to poor prognosis. These mutations specifically alter amino acids in the DLG or ETGE motifs, resulting in aberrant cellular accumulation of Nrf2. Mutant Nrf2 cells display constitutive induction of cytoprotective enzymes and drug efflux pumps, which are insensitive to Keap1-mediated regulation. Suppression of Nrf2 protein levels by siRNA knockdown sensitized cancer cells to oxidative stress and chemotherapeutic reagents. Our results strongly support the contention that constitutive Nrf2 activation affords cancer cells with undue protection from their inherently stressed microenvironment and anti-cancer treatments. Hence, inactivation of the Nrf2 pathway may represent a therapeutic strategy to reinforce current treatments for malignancy. Congruously, the present study also provides in vivo validation of the two-site substrate recognition model for Nrf2 activation by the Keap1-Cul3-based E3 ligase.

KW - Cancer cell microenvironment

KW - Multidrug resistant-associated protein

KW - Oxidative stress

KW - Somatic mutation

KW - Ubiquitin-proteasome system

UR - http://www.scopus.com/inward/record.url?scp=51649130168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649130168&partnerID=8YFLogxK

U2 - 10.1073/pnas.0806268105

DO - 10.1073/pnas.0806268105

M3 - Article

C2 - 18757741

AN - SCOPUS:51649130168

VL - 105

SP - 13568

EP - 13573

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 36

ER -